U.S. FDA Approves Expanded Indication for Lilly's Jaypirca (pirtobrutinib) for Adults with Relapsed or Refractory CLL/SLL

Dec 4, 2025 - 19:00
 0  1
INDIANAPOLIS, Dec. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0